Business Context and Reporting Period
Company: Avalo Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2023
Principal Event: Entry into a Material Definitive Agreement (Sales Agreement) with Oppenheimer & Co. Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the potential capital raise:
- Aggregate Offering Price: Up to $9,032,567
- Commission to Agent: 3.0% of gross proceeds
- Security Type: Common Stock, $0.001 Par Value (Symbol: AVTX)
Material Changes
The filing announces the execution of an "at-the-market" (ATM) sales agreement. This provides the Company with a mechanism to sell shares of common stock from time to time through Oppenheimer & Co. Inc. as sales agent. The offering is subject to the Company's Registration Statement on Form S-3 (File No. 333-271225), which was declared effective by the SEC on May 2, 2023.
Guidance, Outlook, and Risks
- Management Commentary: The Company is not obligated to make any sales of common stock under the Agreement. Sales will be made based on the Company's instructions.
- Termination: The Offering will terminate upon the earlier of the sale of all shares subject to the Agreement or termination of the Agreement in accordance with its terms. Either party may suspend or terminate the Offering upon notice.
- Risks/Contingencies: The filing notes that no offer or sale of securities will occur in any state where such offer would be unlawful prior to registration or qualification. The description of the agreement is qualified by reference to the full text filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the current market price of AVTX to assess potential dilution from the $9,032,567 offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific terms regarding pricing mechanisms and suspension rights.
- Confirm the status of the Form S-3 Registration Statement (File No. 333-271225) to ensure it remains effective for future sales.
- Monitor subsequent filings to determine if and when the Company elects to sell shares under this agreement.